Using Real World Evidence to Build Dynamic Cohorts in Real-Time

After the US Food and Drug Administration (FDA)’s stated that “the clinical trial system is broken,” regulatory agencies began working to formally figure out how real-world evidence will be used in new drug submissions and for new uses of existing drugs. The business potential is huge: organizations can reduce the time and cost of bringing new drugs to market by relying on existing real-world data and new sources of unstructured data, e.g., EHRs and social media. Most importantly, this real-world data can get patient-saving drugs to market more quickly with fewer post-release adverse events.